Paul Calabresis Career Development Award For Clinical Oncology

保罗·卡拉布雷西斯临床肿瘤学职业发展奖

• 批准号: 7932162
• 负责人: ROMAN PEREZ-SOLER
• 金额: $ 103.55万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-29 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7932162
• 关键词: Advisory Committees; Albert Einstein Cancer Center; Cancer Research Project; Clinical; Clinical Investigator; Clinical Oncology; Clinical Research; Commit; County; Educational process of instructing; Foundations; Funding; Genetic; Grant; Institutes; Institution; Instruction; Investigation; K-Series Research Career Programs; Leadership; Malignant Neoplasms; Medical center; Medicine; Mentors; Mission; Monitor; NCI Scholars Program; Population; Principal Investigator; Qualifying; Quality of Care; Research; Research Activity; Research Personnel; Research Support; Research Training; Resources; SECTM1 gene; Therapeutic; Training; Training Programs; Translational Research; Underrepresented Minority; Underserved Population; United States National Institutes of Health; Work; anticancer research; base; cancer research center director; career; college; experience; interdisciplinary collaboration; member; patient oriented; professor; programs; racial and ethnic; research facility; translational medicine

DESCRIPTION (provided by applicant): This proposal seeks to support and develop junior clinical investigators in therapeutic cancer research at the Albert Einstein College of Medicine, through a coordinated program of mentoring, didactic course work, collegial interdisciplinary collaboration, and research support. The leadership for this program is integrated with the Albert Einstein Cancer Center (AECC) and Einstein's Institute for Clinical and Translational Research (ICTR), and based on the major commitment of the Institution to the training and mentoring of young clinical investigators. This Paul Calabresi Scholars Program will select highly qualified clinical and translational investigators, including both MDs and PhDs, each developing their careers in patient-oriented clinical and translational research in cancer therapeutics. Didactic course work will be provided through the K30 and other programs, as needed, with an individualized course of instruction determined for each Scholar. Program oversight will be provided by the Principal Investigator, Dr. Roman Perez-Soler, Professor of Medicine and Associate Director for Clinical Research at the AECC. They will be assisted by an Advisory Committee of leaders of Einstein's cancer research programs, who will select Scholars and monitor each Scholar's progress, and a group of External Advisors formed by PI's of Calabresi Grants at other institutions. The Albert Einstein College of Medicine is ideally suited to implement this program. With its strong foundation in NIH supported investigation, it has invested heavily in building its clinical and translational research activities in cancer under the leadership of the AECC Director, Dr. David Goldman. The PI of this KI2 proposal will assist Dr. Goldman in this mission. Einstein's new Dean, Dr. Allen Spiegel, is deeply committed to clinical and translational investigation; as underscored by a comprehensive new Strategic Research Plan and the recent completion of a new research facility, the Center for Genetic and Translational Medicine. Einstein has an outstanding base of clinical and research training programs in cancer, which will provide a pool of highly qualified candidates for this program. Our primary clinical affiliate, Montefiore Medical Center, provides high quality care to a large, traditionally underserved population in the Bronx, a county of over 1.3 million residents, over 80% of whom are members of ethnic/racial underserved minorities. Given its unique combination of clinical and scientific resources, population diversity, research funding, talented trainees, experienced mentors, teaching programs, research facilities, and institutional commitment, Einstein is poised to succeed in this K12 effort.

描述(由申请者提供)：这项建议寻求通过一个协调的项目来支持和发展阿尔伯特·爱因斯坦医学院癌症治疗性研究中的初级临床研究人员，该计划包括指导、教学课程工作、大学跨学科合作和研究支持。该项目的领导层与阿尔伯特·爱因斯坦癌症中心(AECC)和爱因斯坦临床与转化研究所(ICTR)整合在一起，并基于该研究所对年轻临床研究人员的培训和指导的主要承诺。保罗·卡拉布雷西学者计划将挑选高素质的临床和翻译研究人员，包括医学博士和博士，每个人都在以患者为导向的癌症治疗临床和翻译研究方面发展自己的职业生涯。授课作业将根据需要通过K30和其他计划提供，并为每位学者确定个性化的教学课程。项目监督将由首席研究员、AECC医学教授兼临床研究副主任罗曼·佩雷斯-索勒博士提供。他们将得到一个由爱因斯坦癌症研究项目负责人组成的咨询委员会的协助，该委员会将挑选学者并监督每位学者的进展，以及由卡拉布雷西赠款的PI在其他机构组成的外部顾问小组。阿尔伯特·爱因斯坦医学院非常适合实施这一计划。凭借其在NIH支持的研究方面的强大基础，它在AECC主任David Goldman博士的领导下，投入了大量资金来建立其癌症临床和转化研究活动。这项KI2计划的PI将协助戈德曼博士完成这项任务。爱因斯坦的新院长艾伦·斯皮格尔博士致力于临床和转化性研究；全面的新战略研究计划和最近建成的新研究机构--遗传和转化医学中心--都突显了这一点。爱因斯坦在癌症临床和研究培训项目方面拥有出色的基础，这将为该项目提供一批高度合格的候选人。我们的主要临床附属机构蒙特菲奥里医疗中心为布朗克斯县大量传统上服务不足的人口提供高质量的护理服务，该县有130多万居民，其中80%以上是少数民族/种族服务不足的少数民族成员。鉴于其独特的临床和科学资源组合、人口多样性、研究资金、有才华的受训人员、经验丰富的导师、教学计划、研究设施和机构承诺，爱因斯坦准备在K12努力中取得成功。